Ari Joseph Rosenberg

12PUBLICATIONS
93CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 31, 2026
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

|May 05, 2026
Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.

|Mar 20, 2026
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.

Alexander T Pearson, Jameel Muzaffar, Kedar Kirtane

|May 31, 2025
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma.

Dan P Zandberg, Jacob B Allred, Ari J Rosenberg

|May 27, 2025
Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer.

Ari J Rosenberg, Evgeny Izumchenko, Aditya Juloori

|Oct 31, 2024
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.

Paul L Swiecicki, Emrullah Yilmaz, Ari Joseph Rosenberg

Pageof 2

Frequent Collaborators

6 joint publications

Paul Swiecicki

4 joint publications

Alexander T Pearson

3 joint publications

Justine Yang Bruce

3 joint publications

Emrullah Yilmaz